SCHEMBL1807482

SCHEMBL1807482

CCOC(=O)CCCC1(c2ccc(F)cc2)CCCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 3/20 0.51
SLC6A3 Q01959 3/20 0.46
SLC6A4 P31645 2/20 0.46
SLC6A2 P23975 1/20 0.46
OPRM1 P35372 1/20 0.43
CACNA1G O43497 1/20 0.43
FAAH O00519 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
MAPK1 P28482 1/20 0.39
HTT P42858 1/20 0.39
TSHR P16473 1/20 0.39
LMNA P02545 1/20 0.39
CYP1A2 P05177 1/20 0.39
MAPT P10636 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CNR1 P21554 1/20 0.38
CNR2 P34972 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1807144 0.92 HSD11B1 (0.54) HSD11B1SLC6A3SLC6A4SLC6A2OPRM1
SCHEMBL1806218 0.87 HSD11B1 (0.54) HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G
SCHEMBL434932 0.87 GAA (0.48) SLC6A3SLC6A4SLC6A2OPRM1MEN1
SCHEMBL435013 0.81 HSD11B1 (0.68) HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G
SCHEMBL1807953 0.80 HSD11B1 (0.51) HSD11B1SLC6A3SLC6A4SLC6A2OPRM1
SCHEMBL8484148 0.79 GAA (0.50) SLC6A3SLC6A4SLC6A2OPRM1MEN1
SCHEMBL435377 0.79 SLC6A3 (0.51) HSD11B1SLC6A3SLC6A4SLC6A2KMT2A
SCHEMBL12002389 0.77 SLC6A3 (0.59) HSD11B1SLC6A3SLC6A4SLC6A2CACNA1G
SCHEMBL8485288 0.77 GAA (0.51) SLC6A3SLC6A4SLC6A2OPRM1MEN1
SCHEMBL28984515 0.76 SLC6A3 (0.61) HSD11B1SLC6A3SLC6A4SLC6A2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2592071-B1 Tricyclic heterocyclic compounds BRISTOL MYERS SQUIBB CO (US) 2019-09-18 EP disclosed
US-9216972-B2 Tricyclic heterocyclic compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2015-12-22 US disclosed
CN-102686571-B tricyclic heterocyclic compounds BRISTOL-MYERS SQUIBB CO. (US) 2015-11-25 CN disclosed
EP-2592071-A1 Tricyclic heterocyclic compounds Bristol-Myers Squibb Company (US) 2013-05-15 EP disclosed
CN-102686571-A Tricyclic heterocyclic compounds BRISTOL MYERS SQUIBB CO 2012-09-19 CN disclosed
EP-2493866-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS Bristol-Myers Squibb Company (US) 2012-09-05 EP disclosed
US-20120214767-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2012-08-23 US disclosed
WO-2011059784-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY (US) 2011-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120214767-A1 TRICYCLIC HETEROCYCLIC COMPOUNDS S1PR1, S1PR3, TBXA2R HSD11B1 782/4885SLC6A3 3263/4885SLC6A4 2800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.